OTCMKTS:PFSCF - ProMetic Life Sciences News Headlines

$0.0145
0.00 (0.00 %)
(As of 07/3/2019)
Today's Range
$0.0125
Now: $0.0145
$0.0163
50-Day Range
$0.0145
MA: $0.02
$0.0338
52-Week Range
$0.0125
Now: $0.0145
$0.75
Volume2.46 million shs
Average Volume472,753 shs
Market Capitalization$300.45 million
P/E RatioN/A
Dividend YieldN/A
Beta2.48

Headlines

ProMetic Life Sciences (OTCMKTS PFSCF) News Headlines

Source:
DateHeadline
Prometic Presents New Data on PBI-4050 and its Mechanism of Action on Kidney Fibrosis at the 56th ERA/EDTA CongressPrometic Presents New Data on PBI-4050 and its Mechanism of Action on Kidney Fibrosis at the 56th ERA/EDTA Congress
www.prnewswire.com - June 14 at 4:29 AM
Prometic sets terms for rights offering; shares down 11%Prometic sets terms for rights offering; shares down 11%
seekingalpha.com - May 15 at 9:43 PM
Prometic Life Sciences, Inc. (PFSCF) CEO Ken Galbraith on Q1 2019 Results - Earnings Call TranscriptPrometic Life Sciences, Inc. (PFSCF) CEO Ken Galbraith on Q1 2019 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 7:50 PM
Prometic reports its 2019 first quarter financial resultsPrometic reports its 2019 first quarter financial results
finance.yahoo.com - May 9 at 8:16 AM
Prometic closes $56M capital raisePrometic closes $56M capital raise
seekingalpha.com - April 23 at 6:36 PM
A Retail Investors Look At Prometics Refinancing PlanA Retail Investor's Look At Prometic's Refinancing Plan
seekingalpha.com - April 17 at 7:32 PM
Prometic Life Sciences: An UpdatePrometic Life Sciences: An Update
seekingalpha.com - April 3 at 8:04 PM
Prometic secures additional USD $5 million (CAD $6.7 million) tranche from structured Alpha LP, an affiliate of Thomvest Asset Management Inc., under its existing credit facilitiesPrometic secures additional USD $5 million (CAD $6.7 million) tranche from structured Alpha LP, an affiliate of Thomvest Asset Management Inc., under its existing credit facilities
finance.yahoo.com - March 25 at 9:02 AM
Prometic secures additional $10MPrometic secures additional $10M
seekingalpha.com - February 25 at 7:07 PM
Prometic secures additional USD $10 million (CAD $13.2 million) tranche from Structured Alpha LP, an affiliate of Thomvest Asset Management Inc., under its existing credit facilitiesPrometic secures additional USD $10 million (CAD $13.2 million) tranche from Structured Alpha LP, an affiliate of Thomvest Asset Management Inc., under its existing credit facilities
finance.yahoo.com - February 25 at 8:32 AM
Prometic retains investment bank for strategic transactionsPrometic retains investment bank for strategic transactions
finance.yahoo.com - February 14 at 8:15 AM
National Bank upgrades ProMetic Life Sciences in premarket analyst actionNational Bank upgrades ProMetic Life Sciences in premarket analyst action
seekingalpha.com - January 28 at 8:13 AM
Prof. Simon Best Appointed Interim CEO of Prometic Life SciencesProf. Simon Best Appointed Interim CEO of Prometic Life Sciences
finance.yahoo.com - December 19 at 8:17 AM
Prometic Provides Corporate UpdatePrometic Provides Corporate Update
finance.yahoo.com - November 28 at 8:21 AM
Prometic Life Sciences Inc. (PFSCF) CEO Pierre Laurin On Q3 2018 Results - Earnings Call TranscriptPrometic Life Sciences Inc. (PFSCF) CEO Pierre Laurin On Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 16 at 8:13 AM
Prometic Reports Third Quarter 2018 Financial Results and HighlightsPrometic Reports Third Quarter 2018 Financial Results and Highlights
finance.yahoo.com - November 15 at 8:16 AM
Prometic to Report its Third Quarter 2018 Financial Results and Hold Conference Call / WebcastPrometic to Report its Third Quarter 2018 Financial Results and Hold Conference Call / Webcast
finance.yahoo.com - November 13 at 8:13 AM
Prometic announces positive feedback from FDA Type-C meeting on Typlazim BLAPrometic announces positive feedback from FDA Type-C meeting on Typlazim BLA
seekingalpha.com - October 16 at 5:02 PM
Prometic announces positive feedback from FDA Type-C meeting on Ryplazim™ (plasminogen) BLAPrometic announces positive feedback from FDA Type-C meeting on Ryplazim™ (plasminogen) BLA
finance.yahoo.com - October 16 at 8:19 AM
ProMetic Life Sciences (PFSCF) CEO Pierre Laurin on Q2 2018 Results - Earnings Call TranscriptProMetic Life Sciences' (PFSCF) CEO Pierre Laurin on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - August 15 at 5:36 PM
Prometic Reports Second Quarter 2018 Financial Results and HighlightsPrometic Reports Second Quarter 2018 Financial Results and Highlights
finance.yahoo.com - August 15 at 8:16 AM
Prometic announces the publication of PBI-4050s antifibrotic activity in liver diseases in Journal of Pharmacology and Experimental TherapeuticsPrometic announces the publication of PBI-4050's antifibrotic activity in liver diseases in Journal of Pharmacology and Experimental Therapeutics
finance.yahoo.com - August 10 at 8:15 AM
Prometic receives Rare Pediatric Disease Designation from U.S. FDA for small molecule drug candidate, PBI-4050Prometic receives Rare Pediatric Disease Designation from U.S. FDA for small molecule drug candidate, PBI-4050
finance.yahoo.com - August 7 at 8:14 AM
Prometic Presents New Data on NASH Drug Candidate PBI-4547Prometic Presents New Data on NASH Drug Candidate PBI-4547
finance.yahoo.com - June 22 at 8:37 AM
Prometic Reports Positive Clinical Data from its Intravenous Immunoglobulin (IVIG) Pivotal Phase 3 TrialPrometic Reports Positive Clinical Data from its Intravenous Immunoglobulin (IVIG) Pivotal Phase 3 Trial
finance.yahoo.com - April 30 at 8:17 AM
Prometic Presents New PBI-4050 Clinical Data From Ongoing Alström Syndrome Phase 2 TrialPrometic Presents New PBI-4050 Clinical Data From Ongoing Alström Syndrome Phase 2 Trial
finance.yahoo.com - April 12 at 8:25 AM
Prometic Announces Appointment of Bruce Wendel as Chief Business Development OfficerPrometic Announces Appointment of Bruce Wendel as Chief Business Development Officer
finance.yahoo.com - April 3 at 8:16 AM
Edited Transcript of PLI.TO earnings conference call or presentation 29-Mar-18 12:00pm GMTEdited Transcript of PLI.TO earnings conference call or presentation 29-Mar-18 12:00pm GMT
finance.yahoo.com - March 30 at 8:17 AM
Prometic Reports its Q4-2017 and YE-2017 Financial Results and Provides Update on ActivitiesPrometic Reports its Q4-2017 and YE-2017 Financial Results and Provides Update on Activities
www.benzinga.com - March 29 at 8:20 AM
Prometic to report its Fourth Quarter and Year-End 2017 Financial Results and hold Conference Call / WebcastPrometic to report its Fourth Quarter and Year-End 2017 Financial Results and hold Conference Call / Webcast
finance.yahoo.com - March 26 at 8:17 AM
Prometic receives Rare Pediatric Disease Designation from U.S. FDA for its Inter-Alpha-Inhibitor-ProteinsPrometic receives Rare Pediatric Disease Designation from U.S. FDA for its Inter-Alpha-Inhibitor-Proteins
finance.yahoo.com - March 5 at 8:13 AM
Prometic Announces Realignment of its Clinical Program Priorities for 2018Prometic Announces Realignment of its Clinical Program Priorities for 2018
finance.yahoo.com - February 21 at 8:16 AM
Prometic Announces Publication of PBI-4050s Novel Antifibrotic Mechanism of Action in American Journal of PathologyPrometic Announces Publication of PBI-4050's Novel Antifibrotic Mechanism of Action in American Journal of Pathology
finance.yahoo.com - February 16 at 8:14 AM
Prometic finalizes design of pivotal trial supporting lead drug PBI-4050Prometic finalizes design of pivotal trial supporting lead drug PBI-4050
www.msn.com - January 29 at 9:18 AM
Prometics PBI-4050: Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis (IPF) FinalizedPrometic's PBI-4050: Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis (IPF) Finalized
finance.yahoo.com - January 29 at 9:18 AM
Prometic to host Key Opinion Leader meeting on novel treatments for idiopathic pulmonary fibrosis (IPF)Prometic to host Key Opinion Leader meeting on novel treatments for idiopathic pulmonary fibrosis (IPF)
finance.yahoo.com - January 25 at 3:41 PM
ETFs with exposure to ProMetic Life Sciences, Inc. : December 26, 2017ETFs with exposure to ProMetic Life Sciences, Inc. : December 26, 2017
finance.yahoo.com - December 27 at 2:41 PM
ProMetic Life Sciences, Inc. :PFSCF-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017ProMetic Life Sciences, Inc. :PFSCF-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 6:22 PM
CANADA STOCKS-TSX inches up with fertilizer company gains, railways weighCANADA STOCKS-TSX inches up with fertilizer company gains, railways weigh
www.cnbc.com - December 11 at 10:53 AM
BRIEF-Prometics PBI-4050 Receives Promising Innovative Medicine Designation From UK MHRABRIEF-Prometic's PBI-4050 Receives Promising Innovative Medicine Designation From UK MHRA
www.reuters.com - December 11 at 10:53 AM
Prometics PBI-4050 Receives Promising Innovative Medicine (PIM) Designation From The UK MHRA In The Treatment Of Idiopathic Pulmonary FibrosisPrometic's PBI-4050 Receives Promising Innovative Medicine (PIM) Designation From The UK MHRA In The Treatment Of Idiopathic Pulmonary Fibrosis
finance.yahoo.com - December 11 at 10:53 AM
Pivotal Data for Prometics Intravenous Plasminogen Replacement Therapy to Be Presented at American Society for HematologyPivotal Data for Prometic's Intravenous Plasminogen Replacement Therapy to Be Presented at American Society for Hematology
finance.yahoo.com - December 6 at 10:26 AM
Prometic announces the closing of its USD $80 million (CAD $100 million) line of credit with Structured Alpha LP, an affiliate of Thomvest Asset Management Inc.Prometic announces the closing of its USD $80 million (CAD $100 million) line of credit with Structured Alpha LP, an affiliate of Thomvest Asset Management Inc.
finance.yahoo.com - December 1 at 5:27 PM
BRIEF-Prometic reports positive interim clinical data from IVIG phase 3 trialBRIEF-Prometic reports positive interim clinical data from IVIG phase 3 trial
www.reuters.com - November 23 at 7:26 AM
Prometic Reports Positive Interim Clinical Data from Ongoing Intravenous Immunoglobulin (IVIG) Pivotal Phase 3 TrialPrometic Reports Positive Interim Clinical Data from Ongoing Intravenous Immunoglobulin (IVIG) Pivotal Phase 3 Trial
finance.yahoo.com - November 23 at 7:26 AM
ProMetic Life Sciences Inc. to Host Earnings CallProMetic Life Sciences Inc. to Host Earnings Call
finance.yahoo.com - November 15 at 7:26 AM
This page was last updated on 7/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel